IN8BIO, Inc.

INAB

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001740279

SEC filings (opens in a new tab)

No open-market purchases or sales by IN8BIO, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $5.35M in total; no superinvestor holds it.

Q1 2022 vs. Q4 2021

How the institutions holding IN8BIO, Inc. changed between Q4 2021 and Q1 2022.

All holders in Q1 2022 All holders in Q4 2021

13F holders of INAB: Q4 2021 compared with Q1 2022
Measure	Q4 2021	Q1 2022	Change
Holders	14	14	0
Shares	1.78M	2.05M	+271.6K (+15.3%)
Value	$7.80M	$7.02M	−$784.0K (−10.0%)

New holders (1)

Institutions that held IN8BIO, Inc. at the end of Q1 2022 but not at the end of Q4 2021.

Institutions new to INAB in Q1 2022
Institution	Shares	Value	% of portfolio
Bridgeway Capital Management, LLC	60,000	$208.0K	0.00%

Sold out (1)

Institutions that held IN8BIO, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.

Institutions that sold out of INAB in Q1 2022
Institution	Shares, Q4 2021	Value, Q4 2021
Bank of America Corp	7	$0